Dexcom shares fall on slow revenue growth

Dexcom shares fall on slow revenue growth


Kevin Sayer, CEO, Dexcom

Scott Mlyn | CNBC

Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts’ expectations but showed a decline in U.S. revenue year over year.

Here’s how the company did:

  • Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEG
  • Revenue:  $994 million vs. $990 million expected by LSEG

The company’s revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom’s U.S. revenue declined 2% from $713.6 million the prior year. The company reported net income of $134.6 million, or 34 cents per share, up from $120.7 million, or 29 cents per share, in the same period last year.

Dexcom offers a suite of tools like continuous glucose monitors (CGMs) for patients who have been diagnosed with diabetes. In August, it launched its first over-the-counter product called Stelo, which is intended for adults who do not take insulin.

The company maintained its full fiscal year guidance and expects revenue of $4 billion to $4.05 billion. Last quarter, Dexcom lowered its guidance from the $4.20 billion to $4.35 billion it forecast in the first quarter.

This lowered guidance and a revenue miss caused Dexcom shares to tumble more than 40% following the release of its second-quarter results in July. The company’s CEO Kevin Sayer attributed the challenges to a restructuring of the company’s sales team, fewer new customers than expected and lower revenue per user.

Sayer said in a call with investors Thursday that these problems improved during the third quarter.

The company also announced Teri Lawver, Dexcom’s chief commercial officer, will retire at the end of the year. Lawver will stay on as an adviser through early next year, and Sayer will lead the commercial organization as Dexcom searches for a replacement.



Source

FDA taps biotech industry veteran as RFK Jr.’s top drug regulator 
Health

FDA taps biotech industry veteran as RFK Jr.’s top drug regulator 

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009.  Jason Reed | Reuters The Food and Drug Administration said on Monday it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator. Tidmarsh, an adjunct professor of pediatrics and neonatology […]

Read More
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Health

Weight loss drugs could be a gamechanger for women with a common hormonal disorder

Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images For well over a decade, Grace Hamilton, 27, experienced hair loss, heavy periods, infrequent menstrual cycles, mental health issues and difficulty losing weight without knowing why. It wasn’t until 2021 when she was diagnosed with […]

Read More
Sarepta shares plunge 40% as future of its gene therapy appears at risk
Health

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023. Michael Nagle | Bloomberg | Getty Images Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The […]

Read More